Key Figures Q3 2021
|
SEK m, unless otherwise stated |
2021 Jul-Sep |
2020 Jul-Sep |
2021 Jan-Sep |
2020 Jan-Sep |
2020 Jan-Dec |
|
Net revenues |
145.9 |
150.3 |
421.0 |
504.4 |
663.6 |
|
Cost of goods sold |
-21.3 |
-14.5 |
-58.6 |
-54.3 |
-65.6 |
|
Operating expenses |
-183.7 |
-165.4 |
-512.4 |
-459.0 |
-617.9 |
|
EBIT |
-59.0 |
-29.6 |
-150.0 |
-8.9 |
-19.9 |
|
EBIT margin, % |
-40.5 |
-19.7 |
-35.6 |
-1.8 |
-3.0 |
|
EBITDA |
-47.4 |
-20.9 |
-112.6 |
17.9 |
19.0 |
|
Earnings per share, before dilution, SEK |
-1.51 |
-2.45 |
-4.59 |
-1.00 |
-2.45 |
|
Earnings per share, after dilution, SEK |
-1.51 |
-2.45 |
-4.59 |
-1.00 |
-2.45 |
|
Cash flow from operating activities |
-79.7 |
-12.9 |
-148.4 |
28.0 |
16.8 |
|
Cash and cash equivalents |
588.1 |
593.3 |
588.1 |
593.3 |
505.3 |
Net revenues and EBIT per segment Q3 2021
|
SEK m |
Net Revenues |
EBIT |
||||||||
|
2021 Jul-Sep |
2020 Jul-Sep |
2021 Jan-Sep |
2020 Jan-Sep |
2020 Jan-Dec |
2021 Jul-Sep |
2020 Jul-Sep |
2021 Jan-Sep |
2020 Jan-Jun |
2020 Jan-Dec |
|
|
ZUBSOLV® US |
136.4 |
143.8 |
389.2 |
480.2 |
623.3 |
- |
- |
- |
- |
- |
|
US Pharma – total |
136.4 |
143.8 |
389.2 |
480.2 |
623.3 |
78.5 |
72.4 |
206.1 |
237.2 |
331.2 |
|
Digital Therapeutics (DTx) product sales |
0.4 |
- |
0.8 |
- |
0.0 |
- |
- |
- |
- |
- |
|
Digital Therapeutics (DTx) – total |
0.4 |
- |
0.8 |
- |
0.0 |
-76.4 |
-62.5 |
-186.7 |
-110.1 |
-175.4 |
|
Abstral® royalties |
6.8 |
2.5 |
23.8 |
14.6 |
29.7 |
- |
- |
- |
- |
- |
|
Edluar® royalties |
2.4 |
4.0 |
7.2 |
9.5 |
10.4 |
- |
- |
- |
- |
- |
|
ZUBSOLV® - ex US |
- |
- |
- |
0.1 |
0.1 |
- |
- |
- |
- |
- |
|
HQ & Pipeline segment - total |
9.2 |
6.5 |
31.0 |
24.2 |
40.2 |
-61.2 |
-39.5 |
-169.3 |
-136.0 |
-175.8 |
|
Total |
145.9 |
150.3 |
421.0 |
504.4 |
663.6 |
-59.1 |
-29.6 |
-150.0 |
-8.9 |
-19.9 |
Cash flow Q3 2021
|
SEK m |
2021 Jul-Sep |
2020 Jul-Sep |
2021 Jan-Sep |
2020 Jan-Sep |
2020 Jan-Dec |
|
Cash flow from operating activities |
-79.7 |
-12.9 |
-148.4 |
28.0 |
16.8 |
|
Investment activities |
-20.7 |
-50.2 |
-50.0 |
-160.1 |
-189.2 |
|
Financing activities |
-2.0 |
-4.2 |
256.1 |
-106.9 |
-111.3 |
|
Cash flow (excl exchange rate differences) |
-102.4 |
-67.4 |
57.7 |
-239.1 |
-283.7 |
|
Liquid funds |
588.1 |
593.3 |
588.1 |
593.3 |
505.3 |